Fampridine-

Acorda Therapeutics Reports Third Quarter 2006 Financial Results
Genetic Engineering News (press release) - New Rochelle,NY,USA
... "I was pleased to report in September that the Company achieved positive results from its Phase 3 clinical trial of Fampridine-SR on walking ability in people ...
See all stories on this topic

fampridine acorda

Acorda's Wild Ride
Motley Fool - USA
... Assuming it takes Acorda as long as other drug developers to finalize a trial design, the second phase 3 trial for Fampridine should start sometime in mid-2007 ...
See all stories on this topic

Rodman & Renshaw Healthcare Conference 2006 Presenter Profiles
Business Wire (press release) - San Francisco,CA,USA
... of Fampridine-SR, the Company’s lead product candidate, for the improvement of walking ability in people with MS in September 2006. Additionally, Acorda is ...

rituximab

Biogen Idec Reports Third Quarter 2006 Results
WebWire (press release) - Atlanta,GA,USA
... worldwide sales up 19% to $445 million and RITUXAN® (rituximab) revenues from ... Europe for the treatment of relapsing forms of multiple sclerosis (MS) following ...

tysabri

Biogen Idec Posts 3Q Profit Surge
Houston Chronicle - United States
... Although sales of that medication, Tysabri, totaled just $8 million in the July-September period, sales of an older MS drug, Avonex, rose 19 percent to $445 ...
See all stories on this topic